Clinical Evidence Transcatheter Aortic Valve Replacement

Evolut™ Platform Valve Performance

SURTAVI Clinical Trial (PDF)

Evolut PRO Study

Evolut R US Study

FORWARD Study

Evolut PRO US Study

Evolut PRO Paravalvular Regurgitation


Advanced Sealing


Evolut PRO Valve Performance

Unsurpassed hemodynamics with large mean effective orifice area and low single-digit gradients.

[Back to top]

Evolut R US Study

Unsurpassed valve hemodynamics with large stable effective orifice areas and low single-digit gradients.

Evolut R Paravalvular Regurgitation

High rates of none or trace paravalvular regurgitation out to 12 months.

Evolut R — All Cause Mortality and Disabling Stroke

Proven platform with low rates of mortality and disabling stroke.

Evolut R Additional Safety Outcomes

Low rates of major vascular complications, life threatening or disabling bleeding, pacemaker rate.

[Back to top]

FORWARD Study

30-Day All Cause Mortality

Low 2.0% rate of all-cause mortality at one month.

Additional Safety Outcomes

Low rate of VARC-II safety events at one month.

New Pacemaker Rate

Low rate of new permanent pacemaker.

[Back to top]

Hemodynamic Outcomes

Valve Performance

Unsurpassed hemodynamics with large mean effective orifice area and low single-digit gradients.

Paravalvular Regurgitation

High rates of none or trace paravalvular regurgitation.